Egonil

Fatigue, headache attacks, depressive conditions, problems with the work of the heart - to smooth the discomfort symptomatology, and even completely get rid of pathological symptoms will allow Egonil - a modern neuroleptic. Just do not assign it yourself to yourself - it's a matter of a qualified specialist. It is he who is able to correctly choose the dosage and prescribe the treatment. 

Indications Egonil

A modern neuroleptic that effectively blocks dopamine receptors is Eglonil. This drug was originally developed by the joint French-Ukrainian company Sanofi Winthrop Industry for OOO Sanofi-Aventis (Ukraine) to effectively cope with the problems associated with certain disorders of a person's mental state.

The main indications for the use of Eglonil:

• Psychoses of different genesis, located in the chronic or acute phase of the disease:

• The inhibition of thinking.
• Violation of speech, manifested in difficulties in generating or perceiving speech sentences (agrammatism).
• Abulia - lack of will, lack of initiative, there is understated motivation.
• Confusion of consciousness.
• Absurdity of thoughts, delirium.

• Sluggish schizophrenia is a psychotic personality disorder associated with the disintegration of thought processes and emotional reactions.
• Neuroses of a different nature.
• A variety of psychosomatic diseases:

• Ulcerative lesions of the gastric mucosa and / or duodenum.
• Hemorrhagic rectocolitis.

Release form

On the shelves of modern pharmacies, this medication can be found in a wide range of different dosages, and the form of release is different.

Depending on the clinical picture of the disease, the age of the patient, the doctor can choose the most effective form and dosage of admission.

1. The form of the release is a tablet, produced in two types, differing in concentration of the active substance of sulpiride in them: 0.05 g or 0.2 g. Concomitant chemical compounds are: talcum, silicon dioxide, methylcellulose, lactose monohydrate, potato starch, magnesium stearate. Tablets of a yellow shade. On the plane on one side, the separation groove is clearly visible, and on the other surface one can see "SLP200" embossing. A classic cardboard box is produced with one blister, on which 12 units of medicament are located.
2. Solution for intramuscular injection. The concentration of sulfiride (Sulpiridum) in one ampoule is 0.1 g, additional compounds are sulfuric acid, water, sodium chloride. Liquid without color and odor.
3. The form of release - gelatinous capsules of a yellowish shade. Inside the hard gelatin container is a white, slightly yellowish powder. The concentration of the active substance in the drug is 0.05 g. The carton pack contains three blisters, each containing 10 Egonil units.
4. The solution for internal administration, is mainly assigned to small patients (0.5%). In 100 ml of the drug, 0.5 g of the active ingredient sulpiride is present. The solution is dispensed in bottles of glass with a volume of 200 ml.

Pharmacodynamics

Small volumes of active chemical compounds affect the patient's body directly on the dopaminergic D1 and D2 receptors of the central nervous system, located mainly on the postsynaptic membrane. Blocking dopamine receptors occurs selectively, which is a positive factor for therapy. Pharmacodynamics Eglonil is expressed by a fairly moderate neuroleptic efficacy, which manifests itself in the ability to disinhibit the work of nerve impulses. With small doses administered, the drug is considered an effective stimulant and antidepressant. In the process of therapy with sulpiride, there is no significant sedative effect on the part of the drug in question.

If the dose of the drug is overestimated and is more than 600 mg per day, the antipsychotic result of treatment is able to reduce productive symptoms. You can observe the manifestation of sedative properties. 

Pharmacokinetics

The expected therapeutic effectiveness with oral administration occurs five hours after admission, with intramuscular parenteral method of therapeutic treatment - after thirty minutes. Through this period, the maximum amount of active substance in the blood plasma is reached. When you enter 200 mg of tableted medicine, the figure of the maximum concentration of C _max is 0.73 mg / l. In the case of parenteral administration of 100 mg of the solution, the peak amount of active substance corresponds to approximately 2.2 mg / l.

 Pharmacokinetics Eglonil shows a fairly low bioavailability - only about 25 - 35%. Such a percentage run-up depends on the state of health and the sensitivity of the patient's body. Sulpiride shows excellent distributive and penetrating abilities. The highest rate of invasion is observed in liver and kidney tissue, but the maximum concentration is detected in the pituitary cells.   

The binding properties of sulpiride with blood proteins is 40%. The active substance of the drug is not metabolized, that is, no biotransformation occurs with it. The total clearance of the drug, the rate of clearance of blood plasma, is 126 ml per minute.

The elimination half-life (T _1/2 ) of Eglonil corresponds to about seven hours. Virtually the entire medication (about 92%) is excreted through the kidneys with urine, by glomerular filtration and secretion. About one percent of the administered dose is excreted in breast milk.

Dosing and administration

The drug of this pharmacological group should be prescribed only by a specialist. The doctor uses the method of application and dose of the medicine in question, depending on the disease pattern, the diagnosis and the condition of the patient at the time of appointment.

When diagnosing psychosis, Eglonil is administered as a solution for intramuscular injection. The drug is administered at a dosage of 0.2 to 0.8 g per day. Duration of therapy is about two weeks.

In case of negative manifestations, sulpiride is taken orally in tablets or capsules - a dose of 0.2 to 0.6 g daily, with productive symptoms the method of application is similar, and the daily dosage is prescribed at the rate of 0.8 to 1.6 g.

In the case of manifestation of motor retardation or disorders of psychosomatics, the daily amount of Eglonil taken is 0.1 to 0.2 g.

When diagnosing a stomach ulcer and / or duodenal ulcer, the gastroenterologist ascribes to the patient a medication of 0.15 g daily. The duration of therapy for ulcers is usually four to six weeks.

For small patients, the drug is administered with a solution for internal administration. The daily dose of the medication is calculated individually in each case: 5 to 10 mg per kilogram of the baby's weight. One teaspoon holds 25 mg of solution, and four drops - 1 mg.

Some caveats and recommendations:

1. The medicine must be administered no later than four hours before the proposed bedtime. This will reduce the risk of insomnia.
2. During the period of treatment with the use of Eglonil, it is desirable to refrain from driving vehicles and potentially dangerous moving mechanisms.
3. Exercise caution when entering a medicine if the patient has a history of Parkinson's disease or a tendency to epileptic seizures.
4. Particular care is needed to adjust the dosage in case of kidney failure, as well as children and elderly people.

[1]

Use Egonil during pregnancy

There are no contraindications for prescribing the medicinal product in the period when a woman is carrying a fruit. But there are data confirmed by medical statistics that when introducing the amount of medicine exceeding 200 mg per diem, a small, only born baby could observe a complex of neurological complications manifested by motor disorders (development of extrapyramidal syndrome). Therefore, if you need the use of Eglonil during pregnancy or lactation, it is worthwhile to reduce the therapeutic dosage and reduce the duration of therapy.

Contraindications

Contraindications to the use of Eglonil are insignificant and to those concern only:

• Individual intolerance of constituents of the drug.
• Pheochromocytoma is a hormonally active tumor of chromaffin cells of the sympatoadrenal system of the adrenal or extra-adrenal localization. Or has not yet confirmed and not refuted the suspicion of it.
• Propensity to allergy.

Side effects Egonil

When the dosages and method of administration of the drug are met, side effects of Eglonil occur infrequently. In rare cases, with prolonged therapy or taking significant doses of medication, you can observe:

• The inhibition of actions and thought processes.
• Weight gain.
• Problems with libido, female frigidity and male impotence.
• Extrapyramidal disorders.
• Hyperprolactinemia - increased levels of the hormone prolactin in the blood.
• Decline and drowsiness.
• Gynecomastia - an increase in the size of the mammary glands.
• Dyskinesia - a disorder of coordination of movement: seizures of masticatory muscles, involuntary movement of eye pupils and others.
• Galactorrhea - allocation of milk or colostrum from the nipples, not associated with breastfeeding.
• Amenorrhea is the absence of a menstrual cycle.
• Violation of the regulation of the vascular tone.
• Malignant neuroleptic complications.

Overdose

If the recommended therapeutic dosages are not met or there is a medical need to prescribe large quantities of drug administration, you can get large numbers of its content in the patient's blood. Overdose of sulpiride may be expressed by the appearance of such negative symptoms:

• Disorder of coordination of motor function.
• Muscle spasms, which can lead to crookedness.
• Disturbance of the visual apparatus.
• Nausea.
• Arterial hypertension.
• Increased production of sweat glands secretion.
• Dryness of the oral mucosa.
• Weakness, decrease in general tone.
• Extrapyramidal effect.

If you have one or more symptoms from the list above, you need to inform your doctor about it. He can prescribe hemodialysis, which from this situation will bring at least a slight relief, and even remove the discomfort completely. The main symptomatic therapy is carried out, the introduction of holinoblockers of general action is real.

Interactions with other drugs

The reaction of a sick organism with monotherapy is much easier to predict. With special care should be taken to the appointment of complex therapy, in which two or more drugs are used simultaneously. To achieve the necessary therapeutic effectiveness, while avoiding pathological complications, it is necessary to know the consequences of the interaction of Eglonil with other drugs.

It is strictly prohibited simultaneous administration of sulpiride and such drugs as levodopa, cabergoline and kinagolide - they are mutual antagonists. Do not combine with ethanol and other medications related to the sedative group.

Simultaneous administration of benzodiazepines or derivatives of morphine with Eglonil depressing effect on nerve endings and the rate of impulse responses.

Care should be taken with tandem entry of Eglonil and drugs, the pharmacodynamics of which can provoke a fall in blood pressure.

Do not combine and parallel reception with drugs, after the introduction of which, the risk of developing paroxysmal ventricular tachycardia is real. Medications of the barbiturate group are capable of increasing the inhibition of central nervous system impulses.

It is necessary to exclude tandem reception with such pharmacological chemical compounds:

• Pentamidine.
• Amantadine.
• Antifungal agents.
• Entacapone.
• Dysopyramide. Lizard.
• Lumefantrine.
• Bromocriptine.
• Kinidine.
• The apomorphine.
• Moxifloxacin.
• Selegilin.
• Methadone.
• Halofantrine.
• Sotalol.
• Pramipexole.
•  Ibutilide.
• Chlorpromazine.
• Haloperidol.
• Dofetilide.
• Cisapride.
• Erythromycin.
• And other drugs of these pharmacological groups.

Antihypertensive medications taken together with Eglonil can trigger the development of postural hypotension or a sharp drop in blood pressure. Negative effects on the central nervous system and has a joint reception of sulpiride with tranquilizers .

[2], [3]

Storage conditions

To ensure that during the entire period of the acceptable storage Egonil has not lost its therapeutic characteristics, it is necessary to clearly fulfill all the storage conditions of Eglonil:

• The storage of the medicinal product should be in a darkened room, protected from direct sunlight.
• The temperature should not exceed 30 degrees Celsius.
• The storage location should not be accessible to children.

Shelf life

If all the storage conditions for Egonil were sustained, the shelf-life of the drug in question is three years. However, after the end of the three-year period, further use of the medication is not permissible, in order to avoid the appearance of negative symptoms.